Histogen Inc logo

HSTO - Histogen Inc News Story

$0.793 -0.0  -2.1%

Last Trade - 24/09/21

Sector
Healthcare
Size
Micro Cap
Market Cap £24.2m
Enterprise Value £6.56m
Revenue £1.03m
Position in Universe 6262nd / 7172

BRIEF-Histogen Inc Says Top-Line Data For Phase 1 Study Of Emricasan In Mild-Symptomatic Covid-19 Patients Anticipated In June 2021

Thu 3rd June, 2021 1:24pm
June 3 (Reuters) - Histogen Inc  HSTO.O :
    * HISTOGEN INC - TOP-LINE DATA FOR PHASE 1 STUDY OF
EMRICASAN IN
MILD-SYMPTOMATIC COVID-19 PATIENTS ANTICIPATED IN JUNE 2021
    * HISTOGEN INC - HST 004 SELECTED AS PRODUCT CANDIDATE FOR
SPINAL
DISC REPAIR WITH IND ENABLING ACTIVITIES UNDERWAY
    * HISTOGEN INC - HST 003 TRIAL FOR CARTILAGE REGENERATION IN
KNEE
REMAINS ON-TRACK WITH AN ANTICIPATED PHASE 1/2 STUDY INITIATION
IN JUNE 2021

Source text for Eikon:  ID:nGNX2m4GLJ 
Further company coverage:  HSTO.O 

 ((Reuters.Briefs@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.